Trump’s bill includes a carveout for Big Pharma that will place new limits on the ability of Medicare to negotiate lower drug prices for the public. The bill exempts drugs treating multiple rare conditions from price constraints, and it will let drugmakers pocket $5 billion that might otherwise have been saved by taxpayers. The Biden-era law that enabled Medicare to negotiate drug prices already exempted pharmaceuticals for rare diseases, defined as affecting fewer than 200,000 individuals. The new provision will exempt drugs approved to treat multiple rare diseases,